• Search
      • Search Interactions Search Categories
    • Browse
      • Browse Categories Browse Sources
    • Information
      • About Publications Interaction Types & Directionalities Interaction Score & Query Score API Documentation FAQ Known Data Clients News Contact
    • Downloads
      • Data Source Code

CCND1 Gene Record

  • Summary
  • Interactions
  • Claims
  • CCND1 595 Druggable GenomeClinically ActionableDrug Resistance

    Alternate Names:

    595
    CYCLIN D1
    CCND1
    BCL1
    D11S287E
    PRAD1
    U21B31
    168461
    1582
    ENSG00000110092
    OTTHUMG00000167877
    8
    P24385
    BCL-1
    PRAD1 oncogene
    BCL-1 oncogene
    B-cell lymphoma 1 protein
    G1/S-specific cyclin-D1
    PA75
    T12355

    Gene Info:

    Target Class Miscellaneous
    Target Subclass Miscellaneous
    Target Subclass Cyclin
    Gene Biotype PROTEIN_CODING
    (12 More Sources)

    Gene Categories: Category Details

    KINASE
    DRUG RESISTANCE
    DRUGGABLE GENOME
    CLINICALLY ACTIONABLE
    TRANSCRIPTION FACTOR

    Publications:

    Boutillier et al., 1999, Depolarization regulates cyclin D1 degradation and neuronal apoptosis: a hypothesis about the role of the ubiquitin/proteasome signalling pathway., Eur. J. Neurosci.
    Absenger G et al., 2014, The cyclin D1 (CCND1) rs9344 G>A polymorphism predicts clinical outcome in colon cancer patients treated with adjuvant 5-FU-based chemotherapy., Pharmacogenomics J
    Costea I et al., 2006, Folate cycle gene variants and chemotherapy toxicity in pediatric patients with acute lymphoblastic leukemia., Haematologica
    Costea et al., 2003, The influence of cyclin D1 (CCND1) 870A>G polymorphism and CCND1-thymidylate synthase (TS) gene-gene interaction on the outcome of childhood acute lymphoblastic leukaemia., Pharmacogenetics
    Stendahl et al., 2004, Cyclin D1 overexpression is a negative predictive factor for tamoxifen response in postmenopausal breast cancer patients., Br. J. Cancer
    Christov et al., 2003, Cell proliferation, apoptosis, and expression of cyclin D1 and cyclin E as potential biomarkers in tamoxifen-treated mammary tumors., Breast Cancer Res. Treat.
    Han et al., Cyclin D1 expression and patient outcome after tamoxifen therapy in estrogen receptor positive metastatic breast cancer., Oncol. Rep.
    Gadd et al., 2002, Acetaminophen-induced proliferation of estrogen-responsive breast cancer cells is associated with increases in c-myc RNA expression and NF-kappaB activity., Toxicol. Sci.
    Reddy MV et al., 2014, Discovery of 8-cyclopentyl-2-[4-(4-methyl-piperazin-1-yl)-phenylamino]-7-oxo-7,8-dihydro-pyrido[2,3-d]pyrimidine-6-carbonitrile (7x) as a potent inhibitor of cyclin-dependent kinase 4 (CDK4) and AMPK-related kinase 5 (ARK5)., J Med Chem
    Sharma et al., 2004, Peroxisome proliferator-activated receptor gamma activation modulates cyclin D1 transcription via beta-catenin-independent and cAMP-response element-binding protein-dependent pathways in mouse hepatocytes., J. Biol. Chem.
    Saitoh et al., 2005, Medroxyprogesterone acetate induces cell proliferation through up-regulation of cyclin D1 expression via phosphatidylinositol 3-kinase/Akt/nuclear factor-kappaB cascade in human breast cancer cells., Endocrinology
    Van Poznak et al., 2001, Oral gossypol in the treatment of patients with refractory metastatic breast cancer: a phase I/II clinical trial., Breast Cancer Res. Treat.
    Lee HJ et al., 2018, A selective cyclin-dependent kinase 4, 6 dual inhibitor, Ribociclib (LEE011) inhibits cell proliferation and induces apoptosis in aggressive thyroid cancer., Cancer Lett
    Ogawa et al., 2000, Aberrant expression of p27(Kip1) is associated with malignant transformation of the rat urinary bladder epithelium., Carcinogenesis
    Galli et al., 2004, The effect of alpha- and gamma-tocopherol and their carboxyethyl hydroxychroman metabolites on prostate cancer cell proliferation., Arch. Biochem. Biophys.
    Heathcote DA et al., 2010, A novel pyrazolo[1,5-a]pyrimidine is a potent inhibitor of cyclin-dependent protein kinases 1, 2, and 9, which demonstrates antitumor effects in human tumor xenografts following oral administration., J Med Chem
    Dahan L et al., 2011, Pharmacogenetic profiling and cetuximab outcome in patients with advanced colorectal cancer., BMC Cancer
    Graziano F et al., 2008, Pharmacogenetic profiling for cetuximab plus irinotecan therapy in patients with refractory advanced colorectal cancer., J Clin Oncol
    Zhang W et al., 2006, Cyclin D1 and epidermal growth factor polymorphisms associated with survival in patients with advanced colorectal cancer treated with Cetuximab., Pharmacogenet Genomics
    Ngo BT et al., 2010, Monitoring bortezomib therapy in multiple myeloma: screening of cyclin D1, D2, and D3 via reliable real-time polymerase chain reaction and association with clinico-pathological features and outcome., Leuk Lymphoma
  • BRICICLIB   CCND1

    Interaction Score: 6.18

    Interaction Types & Directionality:
    inhibitor (inhibitory)

    Interaction Info:
    Mechanism of Interaction G1/S-specific cyclin D1 inhibitor
    Direct Interaction yes

    PMIDs:
    None found


    Sources:
    ChemblInteractions TTD

  • URACIL   CCND1

    Interaction Score: 1.55

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    10607743


    Sources:
    NCI

  • RIBOCICLIB   CCND1

    Interaction Score: 0.58

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    29306020


    Sources:
    ClearityFoundationBiomarkers CIViC

  • VITAMIN E   CCND1

    Interaction Score: 0.56

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    14871472


    Sources:
    NCI

  • SELICICLIB   CCND1

    Interaction Score: 0.52

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    21080703


    Sources:
    DTC

  • CETUXIMAB   CCND1

    Interaction Score: 0.29

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    22117530 18349392 16788380


    Sources:
    PharmGKB

  • TAMOXIFEN   CCND1

    Interaction Score: 0.27

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    15138475 12602925 12469160


    Sources:
    NCI CIViC

  • NAVITOCLAX   CCND1

    Interaction Score: 0.26

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    None found


    Sources:
    TTD

  • TROGLITAZONE   CCND1

    Interaction Score: 0.25

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    14764597


    Sources:
    NCI

  • ABEMACICLIB   CCND1

    Interaction Score: 0.22

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    None found


    Sources:
    ClearityFoundationBiomarkers

  • PALBOCICLIB   CCND1

    Interaction Score: 0.2

    Interaction Types & Directionality:
    inhibitor (inhibitory)

    Interaction Info:
    Mechanism of Interaction CDK6/cyclin D1 inhibitor
    Direct Interaction yes

    PMIDs:
    24417566


    Sources:
    DTC ChemblInteractions

  • ALVOCIDIB   CCND1

    Interaction Score: 0.17

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    None found


    Sources:
    DTC

  • ACETAMINOPHEN   CCND1

    Interaction Score: 0.16

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    11896290


    Sources:
    NCI

  • GOSSYPOL   CCND1

    Interaction Score: 0.13

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    11510695


    Sources:
    NCI

  • NIFEDIPINE   CCND1

    Interaction Score: 0.13

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    10051745


    Sources:
    NCI

  • LAPATINIB   CCND1

    Interaction Score: 0.11

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    None found


    Sources:
    PharmGKB

  • METHOTREXATE   CCND1

    Interaction Score: 0.11

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    16870553 12972956


    Sources:
    NCI PharmGKB

  • PROGESTERONE   CCND1

    Interaction Score: 0.09

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    16123159


    Sources:
    NCI

  • BORTEZOMIB   CCND1

    Interaction Score: 0.07

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    20578819


    Sources:
    CIViC

  • FLUOROURACIL   CCND1

    Interaction Score: 0.06

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    23567490


    Sources:
    PharmGKB

  • Ensembl: ENSG00000110092

    • Version: 101_38

    Alternate Names:
    CCND1 Ensembl Gene Name

    Gene Info:
    Gene Biotype PROTEIN_CODING

    Publications:

  • TdgClinicalTrial: P24385

    • Version: January-2014

    Alternate Names:
    CCND1 Gene Symbol

    Gene Info:
    Target Class Miscellaneous
    Target Subclass Miscellaneous
    Target Subclass Cyclin

    Publications:

  • PharmGKB: CCND1

    • Version: 18-August-2020

    Alternate Names:
    PA75 PharmGKB ID

    Gene Info:

    Publications:
    Absenger G et al., 2014, The cyclin D1 (CCND1) rs9344 G>A polymorphism predicts clinical outcome in colon cancer patients treated with adjuvant 5-FU-based chemotherapy., Pharmacogenomics J
    Dahan L et al., 2011, Pharmacogenetic profiling and cetuximab outcome in patients with advanced colorectal cancer., BMC Cancer
    Zhang W et al., 2006, Cyclin D1 and epidermal growth factor polymorphisms associated with survival in patients with advanced colorectal cancer treated with Cetuximab., Pharmacogenet Genomics

  • CIViC: CCND1

    • Version: 14-September-2020

    Alternate Names:
    595 Entrez Gene ID
    8 CIViC Gene ID

    Gene Info:

    Gene Categories:
    DRUG RESISTANCE

    Publications:
    Lee HJ et al., 2018, A selective cyclin-dependent kinase 4, 6 dual inhibitor, Ribociclib (LEE011) inhibits cell proliferation and induces apoptosis in aggressive thyroid cancer., Cancer Lett
    Stendahl et al., 2004, Cyclin D1 overexpression is a negative predictive factor for tamoxifen response in postmenopausal breast cancer patients., Br. J. Cancer
    Ngo BT et al., 2010, Monitoring bortezomib therapy in multiple myeloma: screening of cyclin D1, D2, and D3 via reliable real-time polymerase chain reaction and association with clinico-pathological features and outcome., Leuk Lymphoma

  • NCI: CCND1

    • Version: 14-September-2017

    Alternate Names:

    Gene Info:

    Publications:
    Boutillier et al., 1999, Depolarization regulates cyclin D1 degradation and neuronal apoptosis: a hypothesis about the role of the ubiquitin/proteasome signalling pathway., Eur. J. Neurosci.
    Shinozaki et al., Cyclin D1 expression in the intestinal mucosa and tumors of Apc1638N mice., Anticancer Res.
    Shen et al., 2006, p53-independent G1 cell cycle arrest of human colon carcinoma cells HT-29 by sulforaphane is associated with induction of p21CIP1 and inhibition of expression of cyclin D1., Cancer Chemother. Pharmacol.

  • DTC: CCND1

    • Version: 02-September-2020

    Alternate Names:

    Gene Info:

    Publications:
    Heathcote DA et al., 2010, A novel pyrazolo[1,5-a]pyrimidine is a potent inhibitor of cyclin-dependent protein kinases 1, 2, and 9, which demonstrates antitumor effects in human tumor xenografts following oral administration., J Med Chem
    Reddy MV et al., 2014, Discovery of 8-cyclopentyl-2-[4-(4-methyl-piperazin-1-yl)-phenylamino]-7-oxo-7,8-dihydro-pyrido[2,3-d]pyrimidine-6-carbonitrile (7x) as a potent inhibitor of cyclin-dependent kinase 4 (CDK4) and AMPK-related kinase 5 (ARK5)., J Med Chem

  • HingoraniCasas: ENSG00000110092

    • Version: 31-May-2017

    Alternate Names:
    ENSG00000110092 Gene Symbol
    CCND1 Ensembl Id

    Gene Info:

    Gene Categories:
    DRUGGABLE GENOME

    Publications:

  • ChemblInteractions: BCL1

    • Version: chembl_23

    Alternate Names:
    PRAD1 GENE_SYMBOL
    CCND1 GENE_SYMBOL
    G1/S-specific cyclin-D1 UNIPROT

    Gene Info:

    Publications:

  • Tempus: CCND1

    • Version: 11-November-2018

    Alternate Names:
    CCND1 Gene Symbol

    Gene Info:

    Gene Categories:
    CLINICALLY ACTIONABLE

    Publications:

  • TTD: G1/S-specific cyclin-D1

    • Version: 2020.06.01

    Alternate Names:
    CCND1 TTD Gene Abbreviation
    T12355 TTD Target ID

    Gene Info:

    Publications:

  • Pharos: CCND1

    • Version: 01-February-2022

    Alternate Names:
    G1/S-specific cyclin-D1 Gene Name
    P24385 UniProt ID

    Gene Info:

    Gene Categories:
    KINASE, TRANSCRIPTION FACTOR

    Publications:

  • MskImpact: CCND1

    • Version: May-2015

    Alternate Names:

    Gene Info:

    Gene Categories:
    CLINICALLY ACTIONABLE

    Publications:

  • ClearityFoundationBiomarkers: CCND1

    • Version: 26-July-2013

    Alternate Names:

    Gene Info:

    Publications:

  • FoundationOneGenes: CCND1

    • Version: 03-September-2020

    Alternate Names:

    Gene Info:

    Gene Categories:
    CLINICALLY ACTIONABLE

    Publications:

  • CarisMolecularIntelligence: CCND1

    • Version: 04-September-2020

    Alternate Names:

    Gene Info:

    Gene Categories:
    CLINICALLY ACTIONABLE

    Publications:

  • Oncomine: CCND1

    • Version: v3

    Alternate Names:

    Gene Info:

    Gene Categories:
    CLINICALLY ACTIONABLE

    Publications:

Disclaimer: This resource is intended for purely research purposes. It should not be used for emergencies or medical or professional advice.

A finding of a drug-gene interaction or potentially druggable category does not necessarily indicate effectiveness (or lack thereof) of any drug or treatment regimen. A finding of no interaction or no potentially druggable category does not necessarily indicate lack of effectiveness of any drug or treatment regimen. Drug-gene interactions or potentially druggable categories are not presented in ranked order of potential or predicted efficacy.

The dgidb.org website does not provide any medical or healthcare products, services or advice, and is not for medical emergencies or urgent situations. IF YOU THINK YOU MAY HAVE A MEDICAL EMERGENCY, CALL YOUR DOCTOR OR 911 IMMEDIATELY. Information contained on this website is not a substitute for a doctor's medical judgment or advice. We recommend that you discuss your specific, individual health concerns with your doctor or health care professional.

DGIdb (v4.2.0 - sha1 afd9f30b) • Last updated 2020-10-21